Skip to main content
Defiance International

Published study records

Study records for BPC-157

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

323 study records.

4 evidence-verified · 288 citation-verified · 31 citation-only

Verified records by research setting

  • Human research: 39
  • In vitro: 13
  • In vivo/preclinical: 240
  • Review/meta-analysis: 0
  • Other: 0
Filter study recordsReset filters

Current study records

Study type: Human research · Status: Evidence verified by machine against declared source

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

International journal of molecular sciences · 2026

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • BPC-157: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Evidence verified by machine against declared source

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

Pharmaceuticals (Basel, Switzerland) · 2025

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • BPC-157: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

This paper aims at presenting the BPC 157-induced therapeutic effects, which have been confirmed in several reports, but also to address probable side effects that may, however, result from the mechanism of action and the activation of signaling pathways by the peptide.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Evidence verified by machine against declared source

Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.

Pharmaceuticals (Basel, Switzerland) · 2025

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • BPC-157: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.

Drug design, development and therapy · 2015

Study scale: Male Sprague Dawley rats (n=58) weighing 160 g–220 g were chosen for the experiments.

Abstract only: Open source record

Product or molecular entity relationships

  • BPC-157: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The present study aimed to investigate the wound healing effects of synthesized BPC-157 on alkali-burned rats and elucidate its mechanisms of action.

Study design

Not reported in the declared source.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Male Sprague Dawley rats (n=58) weighing 160 g–220 g were chosen for the experiments.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

To assess the influence of BPC-157 on cell growth, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay was used.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

BPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review of Clinical Efficacy and Safety

Quality in Sport · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.

Pharmaceuticals (Basel, Switzerland) · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics

Pharmaceuticals (Basel, Switzerland) · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation identity verified

Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery

Journal of Clinical Medicine · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Sports medicine (Auckland, N.Z.) · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias.

Pharmaceuticals (Basel, Switzerland) · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation identity verified

BPC-157 and the gut–brain axis: emerging links between cytoprotection and neuroregeneration

Annales Academiae Medicae Silesiensis · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers

Pharmaceutics · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • BPC-157: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.